Ebola virus: unravelling pathogenesis to combat a deadly disease

Trends in Molecular Medicine

Volumn 12, Issue 5, 2006, Pages 206-215

  Hoenen, Thomas ^a,b   Groseth, Allison ^a,c   Falzarano, Darryl ^a,c   Feldmann, Heinz ^a,c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; EBOLA VACCINE; VIRUS PROTEIN;

CLINICAL FEATURE; DISEASE SEVERITY; DRUG SYNTHESIS; EBOLA VIRUS; EPIDEMIC; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; REVIEW; TARGET CELL; VASCULAR DISEASE; VIRUS HEMORRHAGIC FEVER;

ANIMALS; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

ANIMALIA; EBOLA VIRUS;

EID: 33646584499     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2006.03.006     Document Type: Review

References (95)

1. Feldmann H., et al. Filoviridae. In: Fauqet C.M., et al. (Ed). Virus Taxonomy, Eighth Report of the International Committee on Taxonomy of Viruses (2004), Elsevier Academic Press, San Diego, CA 645-653
2. Sanchez, A. et al. (2001) Filoviridae - Marburg and Ebola viruses. In Fields Virology (4th edn) (Knipe, D. and Howley, P., eds.), pp. 1279-1304, Lippincott Williams and Wilkins, Philadelphia, PA
3. Jezek Z., et al. Ebola between outbreaks: intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of the Congo, 1981-1985. J. Infect. Dis. 179 Suppl 1 (1999) S60-S64
4. Feldmann H., et al. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 3 (2003) 677-685
5. Roels T.H., et al. Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. J. Infect. Dis. 179 Suppl 1 (1999) S92-S97
6. Leroy E.M., et al. Fruit bats as reservoirs of Ebola virus. Nature 438 (2005) 575-576
7. Swanepoel R., et al. Experimental inoculation of plants and animals with Ebola virus. Emerg. Infect. Dis. 2 (1996) 321-325
8. Bwaka M.A., et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J. Infect. Dis. 179 Suppl 1 (1999) S1-S7
9. Formenty P., et al. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J. Infect. Dis. 179 Suppl 1 (1999) S48-S53
10. Sureau P.H. First hand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev. Infect. Dis. 11 Suppl 4 (1989) S790-S793
11. Fisher-Hoch S.P., et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J. Infect. Dis. 152 (1985) 887-894
12. Geisbert T.W., and Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat. Med. 10 12 Suppl (2004) S110-S121
13. Towner J.S., et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J. Virol. 78 (2004) 4330-4341
14. Sanchez A., et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol. 78 (2004) 10370-10377
15. Rodriguez L.L., et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 Suppl 1 (1999) S170-S176
16. Bray M. Pathogenesis of viral hemorrhagic fever. Curr. Opin. Immunol. 17 (2005) 399-403
17. Hensley L.E., et al. Ebola and Marburg viruses: pathogenesis and development of countermeasures. Curr. Mol. Med. 5 (2005) 761-772
18. Ryabchikova E.I., et al. Animal pathology of filoviral infections. Curr. Top. Microbiol. Immunol. 235 (1999) 145-173
19. Bray M., et al. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178 (1998) 651-661
20. Connolly B.M., et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179 Suppl 1 (1999) S203-S217
21. Volchkov V.E., et al. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277 (2000) 147-155
22. Ebihara, H. et al. (2005) Genetic determinants of mouse-adaptation of Ebola virus. In Abstracts of the XIII International Congress of Virology, pp. 21-22, American Society for Microbiology, Washington, DC
23. Mestas J., and Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172 (2004) 2731-2738
24. Geisbert T.W., et al. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest. 80 (2000) 171-186
25. Feldmann H., et al. Therapy and prophylaxis of Ebola virus infections. Curr. Opin. Investig. Drugs 6 (2005) 823-830
26. Geisbert T.W., et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8 (2002) 503-507
27. Ryabchikova E.I., et al. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J. Infect. Dis. 179 Suppl 1 (1999) S199-S202
28. Mahanty S., and Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 4 (2004) 487-498
29. Volchkov V.E., et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291 (2001) 1965-1969
30. Neumann G., et al. Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J. Virol. 76 (2002) 406-410
31. Ebihara H., et al. The role of reverse genetics systems in studying viral hemorrhagic fevers. Thromb. Haemost. 94 (2005) 240-253
32. Schnittler H.J., and Feldmann H. Marburg and Ebola hemorrhagic fevers: does the primary course of infection depend on the accessibility of organ-specific macrophages?. Clin. Infect. Dis. 27 (1998) 404-406
33. Stroher U., et al. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75 (2001) 11025-11033
34. Zaki S.R., et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J. Infect. Dis. 179 Suppl 1 (1999) S36-S47
35. Geisbert T.W., et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163 (2003) 2347-2370
36. Gibb T.R., et al. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125 (2001) 233-242
37. Harcourt B.H., et al. Ebola virus selectively inhibits responses to interferons, but not to interleukin-1β, in endothelial cells. J. Virol. 73 (1999) 3491-3496
38. Geisbert T.W., et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am. J. Pathol. 163 (2003) 2371-2382
39. Zaki S.R., and Goldsmith C.S. Pathologic features of filovirus infections in humans. Curr. Top. Microbiol. Immunol. 235 (1999) 97-116
40. Becker S., et al. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J. Gen. Virol. 76 (1995) 393-399
41. Marzi A., et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol. 78 (2004) 12090-12095
42. Takada A., et al. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 78 (2004) 2943-2947
43. Leroy E.M., et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 355 (2000) 2210-2215
44. Bray M. The role of the type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82 (2001) 1365-1373
45. Gupta M., et al. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1α and TNF-α and inhibit poly-IC-induced IFN-α in vitro. Virology 284 (2001) 20-25
46. Harcourt B.H., et al. Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology 252 (1998) 179-188
47. Basler C.F., and Palese P. Modulation of innate immunity by filoviruses. In: Klenk H.D., and Feldmann H. (Eds). Ebola and Marburg viruses (2004), Horizon Bioscience, Norfolk, U.K. 305-349
48. Basler C.F., et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12289-12294
49. Halfmann, P.J. and Kawaoka, Y. (2005) Ebola VP24 inhibits type I interferon signaling. In Abstracts of the XIII International Congress of Virology, p. 81, American Society for Microbiology, Washington, DC
50. Jahrling P.B., et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 179 Suppl 1 (1999) S224-S234
51. Bosio C.M., et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188 (2003) 1630-1638
52. Mahanty S., et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170 (2003) 2797-2801
53. Bosio C.M., et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 326 (2004) 280-287
54. Reed D.S., et al. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol. 17 (2004) 390-400
55. Hensley L.E., et al. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80 (2002) 169-179
56. Tosi M.F. Innate immune responses to infection. J. Allergy Clin. Immunol. 116 (2005) 241-249
57. Baize S., et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5 (1999) 423-426
58. Ksiazek T.G., et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179 Suppl 1 (1999) S177-S187
59. Schnittler H.J., et al. The role of endothelial cells in filovirus hemorrhagic fever. In: Klenk H.D., and Feldmann H. (Eds). Ebola and Marburg viruses (2004), Horizon Bioscience, Norfolk, U.K. 179-303
60. Schnittler H.J., and Feldmann H. Viral hemorrhagic fever - a vascular disease?. Thromb. Haemost. 89 (2003) 967-972
61. Villinger F., et al. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J. Infect. Dis. 179 Suppl 1 (1999) S188-S191
62. Feldmann H., et al. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J. Virol. 70 (1996) 2208-2214
63. Wahl-Jensen V.M., et al. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol. 79 (2005) 10442-10450
64. Landry D.W., and Oliver J.A. The pathogenesis of vasodilatory shock. N. Engl. J. Med. 345 (2001) 588-595
65. Baize S., et al. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128 (2002) 163-168
66. Szotowski B., et al. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ. Res. 96 (2005) 1233-1239
67. Levi M. Current understanding of disseminated intravascular coagulation. Br. J. Haematol. 124 (2004) 567-576
68. Geisbert T.W., et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188 (2003) 1618-1629
69. Geisbert T.W., et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362 (2003) 1953-1958
70. Feldmann H., et al. Biosynthesis and role of filoviral glycoproteins. J. Gen. Virol. 82 (2001) 2839-2848
71. Yang Z.Y., et al. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6 (2000) 886-889
72. Simmons G., et al. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76 (2002) 2518-2528
73. Chan S.Y., et al. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Gen. Virol. 81 (2000) 2155-2159
74. Dolnik O., et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 23 (2004) 2175-2184
75. Volchkova V.A., et al. Δ-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 265 (1999) 164-171
76. Sanchez A., et al. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72 (1998) 6442-6447
77. Kindzelskii A.L., et al. Ebola virus secretory glycoprotein (sGP) diminishes Fc γ RIIIB-to-CR3 proximity on neutrophils. J. Immunol. 164 (2000) 953-958
78. Yang Z., et al. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279 (1998) 1034-1037
79. Sui J., and Marasco W.A. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 303 (2002) 9-14
80. Maruyama T., et al. Ebola virus, neutrophils, and antibody specificity. Science 282 (1998) 843
81. Ito H., et al. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75 (2001) 1576-1580
82. Volchkov V.E., et al. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett. 305 (1992) 181-184
83. Ignatyev G.M. Immune response to filovirus infections. Curr. Top. Microbiol. Immunol. 235 (1999) 205-217
84. Borio L., et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. J. Am. Med. Assoc. 287 (2002) 2391-2405
85. Pushko P., et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19 (2000) 142-153
86. Borisevich I.V., et al. Preparation of hyperimmune horse serum against Ebola virus. Vopr. Virusol. 40 (1995) 270-273
87. Jahrling P.B., et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl. 11 (1996) 135-140
88. Mupapa K., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179 Suppl 1 (1999) S18-S23
89. Warfield K.L., et al. Filovirus-like particles as vaccines and discovery tools. Expert Rev. Vaccines 4 (2005) 429-440
90. Sullivan N.J., et al. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 (2000) 605-609
91. Sullivan N.J., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 (2003) 681-684
92. Kobinger G.P., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology (2005)
93. Garbutt M., et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78 (2004) 5458-5465
94. Jones S.M., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11 (2005) 786-790
95. Bukreyev A., et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 80 (2006) 2267-2279